CHMP upheld earlier opinions that Translarna is not of significant benefit to DMD due to nonsense mutations; European ...

EMA re-confirms non-renewal of conditional marketing authorisation of Duchenne muscular dystrophy medicine, Translarna: Amsterdam, The Netherlands Monday, October 21, 2024, 10:00 ...

The drug's active substance, ataluren, helps cells bypass the mutation to produce functional dystrophin protein. Following ...

PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has maintained its negative opinion on the renewal ...

The agency has reconfirmed its recommendation to not give positive opinion to Translarna (ataluren) after a reexamination of the available data.

Seaport Therapeutics Inc. has followed up its recent fundraiser with an oversubscribed $225 million series B financing that will help set it on the path to a phase IIb study of major depressive ...

PTCT announced positive results on two different long-term extension studies on vatiquinone.The company also announced ...

Moving drugs from the lab bench to pharmacy shelves is no small task. In this article we delve into the role regulatory ...

António Guterres’s invitation to the Kremlin’s Kazan meeting shows the failure of the United Nations ...

In the first days of standard time, sunrise in the Bay Area will be around ...

Opinion to be reviewed by European Commission - WARREN, N.J., Oct. 18, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) ann ...